<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01942694</url>
  </required_header>
  <id_info>
    <org_study_id>U01DK098245</org_study_id>
    <secondary_id>U01DK098245</secondary_id>
    <nct_id>NCT01942694</nct_id>
    <nct_alias>NCT02015052</nct_alias>
    <nct_alias>NCT02239471</nct_alias>
  </id_info>
  <brief_title>Vitamin D and Type 2 Diabetes Study</brief_title>
  <acronym>D2d</acronym>
  <official_title>Vitamin D and Type 2 Diabetes Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Office of Dietary Supplements (ODS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the Vitamin D and type 2 diabetes (D2d) study is to determine if vitamin D&#xD;
      supplementation works to delay the onset of type 2 diabetes in people at risk for the disease&#xD;
      and to gain a better understand how vitamin D affects glucose (sugar) metabolism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of the Vitamin D and type 2 diabetes (D2d) study is to determine if vitamin D&#xD;
      supplementation works to delay the onset of type 2 diabetes in people at risk for the disease&#xD;
      and to gain a better understand how vitamin D affects glucose (sugar) metabolism. Researchers&#xD;
      at US sites will enroll people with pre-diabetes (people who have higher than normal blood&#xD;
      glucose level but not high enough to meet the diagnosis of diabetes). The study will enroll&#xD;
      participants over approximately 2 years and participants will be followed for approximately 3&#xD;
      years. Participants will receive either Vitamin D or a placebo by chance. Participants will&#xD;
      take 1 pill a day for the duration of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Actual">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Development of Diabetes</measure>
    <time_frame>Approximately 48 months</time_frame>
    <description>New-onset diabetes was based on annual glycemic testing of fasting plasma glucose, glycated hemoglobin, and 2-hour post-load plasma glucose and semiannual testing of fasting plasma glucose and glycated hemoglobin. If two or three of the glycemic measures met the 2010 ADA thresholds for diabetes, the participant was considered to have met the diabetes outcome. When only the measure for fasting plasma glucose or glycated hemoglobin met the threshold, confirmatory testing was performed for the positive measure within 8 weeks. If only the measure for 2-hour post-load plasma glucose met the threshold, then a 75-g oral glucose tolerance test to reassess all three glycemic measures was repeated. If the repeat measure was positive or both fasting plasma glucose and glycated hemoglobin were positive (in the case of a repeat oral glucose tolerance test), than the participant was considered to have met the diabetes outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: 25OHD Concentration</measure>
    <time_frame>Approximately 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Race (as a Proxy for Skin Pigmentation)</measure>
    <time_frame>Approximately 48 months</time_frame>
    <description>Race and ethnic group were reporting by the participant. The category &quot;other&quot; includes American Indian or Alaska Native; Native Hawaiian or other Pacific Islander; and other race. Ethnic group includes any race.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Pre-diabetes Criteria (Two vs. Three Criteria)</measure>
    <time_frame>Approximately 48 months</time_frame>
    <description>Participants met at least two of three glycemic criteria for prediabetes: fasting plasma glucose level, 100 to 125 mg per deciliter (5.6 to 6.9 mmol per liter); plasma glucose level 2 hours after a 75-g oral glucose load, 140 to 199 mg per deciliter (7.8 to 11.0 mmol per liter) (impaired glucose tolerance); and glycated hemoglobin level, 5.7 to 6.4% (39 to 47 mmol per mole).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: BMI</measure>
    <time_frame>Approximately 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Waist Circumference</measure>
    <time_frame>Approximately 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Age</measure>
    <time_frame>Approximately 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Geographic Location (as a Proxy for Sun Exposure)</measure>
    <time_frame>Approximately 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Calcium Intake From Supplements</measure>
    <time_frame>Approximately 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Plasma 25OHD Concentration.</measure>
    <time_frame>Approximately 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events.</measure>
    <time_frame>Approximately 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Pressure as a Continuous Variable.</measure>
    <time_frame>Approximately 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinue Study Pills.</measure>
    <time_frame>Approximately 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FPG as a Continuous Variable.</measure>
    <time_frame>Every 12 months for approximately 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 2hPG as a Continuous Variable.</measure>
    <time_frame>Every 12 months for approximately 48 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c as a Continuous Variable.</measure>
    <time_frame>Every 6 months for approximately 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Insulin Resistance (Derived From the OGTT).</measure>
    <time_frame>Every 12 months for approximately 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Beta Cell Secretion (Derived From the OGTT)</measure>
    <time_frame>Every 12 months for approximately 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of Characteristics Associated With the Variability in Achieved 25OHD Concentration.</measure>
    <time_frame>Every 12 months for approximately 48 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Sex</measure>
    <time_frame>Approximately 48 months.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Ethnicity</measure>
    <time_frame>Approximately 48 months.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: 2 Hour Plasma Glucose</measure>
    <time_frame>Approximately 48 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to Development of Cancer.</measure>
    <time_frame>Approximately 48 months.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to Development of Cardiovascular Event.</measure>
    <time_frame>Approximately 48 months.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Cancer in a Pre-diabetes Population Defined by the Modern American Diabetes Association Criteria.</measure>
    <time_frame>Approximately 48 months.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Cardiovascular Disease in a Pre-diabetes Population Defined by the Modern American Diabetes Association Criteria.</measure>
    <time_frame>Approximately 48 months.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of Life and Mood Scores in Pre-diabetes Population Using a Validated Instrument (PROMIS-29 Profile v2.0 and a General Question on Perception of Overall Health From the PROMIS Scale 1.2).</measure>
    <time_frame>One time assessment at the month 24 visit.</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2423</enrollment>
  <condition>Prediabetes</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One pill daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D (Cholecalciferol)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One vitamin D pill daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D (Cholecalciferol)</intervention_name>
    <description>Vitamin D (Cholecalciferol) 4000 IU, administered as 1 soft-gel pill daily by mouth.</description>
    <arm_group_label>Vitamin D (Cholecalciferol)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as one soft-gel pill daily by mouth</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pre-diabetes (&quot;at increased risk for diabetes&quot;) defined by meeting 2-out-of-3 of the&#xD;
             following glycemic criteria at the baseline visit:&#xD;
&#xD;
               1. Fasting plasma glucose (FPG) 100-125 mg/dL&#xD;
&#xD;
               2. 2-hour plasma glucose (2hPG) 140-199 mg/dL&#xD;
&#xD;
               3. Hemoglobin A1c (HbA1c) 5.7-6.4%&#xD;
&#xD;
          2. Age ≥ 30 years .(≥25 years for people of the following races: American-Indian, Alaska&#xD;
             Native, Native Hawaiian or Other Pacific Islander).&#xD;
&#xD;
          3. Body Mass Index ≥ 24.0 (22.5 for Asians) and ≤ 42.0 kg/m2&#xD;
&#xD;
          4. Provision of signed and dated written informed consent prior to any study procedures.&#xD;
&#xD;
        Major Exclusion Criteria:&#xD;
&#xD;
          1. Diabetes based on either of the following criteria:&#xD;
&#xD;
               1. History (past 1 year) of hypoglycemic pharmacotherapy (oral or injectable&#xD;
                  medication approved by the FDA for type 2 diabetes), used for any condition (e.g.&#xD;
                  pre-diabetes, diabetes, polycystic ovarian syndrome.&#xD;
&#xD;
               2. Meeting the diagnosis criteria for diabetes&#xD;
&#xD;
          2. History (past 3 years) of hyperparathyroidism, nephrolithiasis or hypercalcemia.&#xD;
&#xD;
          3. Pregnancy (past 1 year by report or positive pregnancy test at screening), intent to&#xD;
             become pregnant in the next 4 years or unprotected intercourse. History of gestational&#xD;
             diabetes is not an exclusion criterion.&#xD;
&#xD;
          4. Currently breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anastassios Pittas, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southwest American Indian Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado, Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando VA Medical Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Translational Research Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta VA Medical Center</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Health Sciences</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Community Clinical Research Center</name>
      <address>
        <city>Hyattsville</city>
        <state>Maryland</state>
        <zip>20782</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Partners Riverside Clinic</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omaha VA Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Center for Health Research</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Health Science Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 9, 2013</study_first_submitted>
  <study_first_submitted_qc>September 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2013</study_first_posted>
  <results_first_submitted>August 10, 2020</results_first_submitted>
  <results_first_submitted_qc>August 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 9, 2020</results_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prediabetes</keyword>
  <keyword>Vitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT01942694/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT01942694/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>One pill daily&#xD;
Placebo: Administered as one soft-gel pill daily by mouth</description>
        </group>
        <group group_id="P2">
          <title>Vitamin D (Cholecalciferol)</title>
          <description>One vitamin D pill daily&#xD;
Vitamin D (Cholecalciferol): Vitamin D (Cholecalciferol) 4000 IU, administered as 1 soft-gel pill daily by mouth.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1212"/>
                <participants group_id="P2" count="1211"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1211"/>
                <participants group_id="P2" count="1211"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>One pill daily&#xD;
Placebo: Administered as one soft-gel pill daily by mouth</description>
        </group>
        <group group_id="B2">
          <title>Vitamin D (Cholecalciferol)</title>
          <description>One vitamin D pill daily&#xD;
Vitamin D (Cholecalciferol): Vitamin D (Cholecalciferol) 4000 IU, administered as 1 soft-gel pill daily by mouth.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1212"/>
            <count group_id="B2" value="1211"/>
            <count group_id="B3" value="2423"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.4" spread="10.0"/>
                    <measurement group_id="B2" value="59.6" spread="9.9"/>
                    <measurement group_id="B3" value="60.0" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="545"/>
                    <measurement group_id="B2" value="541"/>
                    <measurement group_id="B3" value="1086"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="667"/>
                    <measurement group_id="B2" value="670"/>
                    <measurement group_id="B3" value="1337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="225"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1107"/>
                    <measurement group_id="B2" value="1091"/>
                    <measurement group_id="B3" value="2198"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="315"/>
                    <measurement group_id="B2" value="301"/>
                    <measurement group_id="B3" value="616"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="806"/>
                    <measurement group_id="B2" value="810"/>
                    <measurement group_id="B3" value="1616"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1212"/>
                    <measurement group_id="B2" value="1211"/>
                    <measurement group_id="B3" value="2423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting plasma glucose (mg/dl)</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107.8" spread="7.4"/>
                    <measurement group_id="B2" value="108.0" spread="7.4"/>
                    <measurement group_id="B3" value="107.9" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>2-Hr post-load plasma glucose (mg/dl)</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137.6" spread="34.3"/>
                    <measurement group_id="B2" value="136.9" spread="34.3"/>
                    <measurement group_id="B3" value="137.2" spread="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycated hemoglobin (%)</title>
          <units>%</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.9" spread="0.2"/>
                    <measurement group_id="B2" value="5.9" spread="0.2"/>
                    <measurement group_id="B3" value="5.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum 25-hydroxyvitamin D (ng/ml)</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.2" spread="10.1"/>
                    <measurement group_id="B2" value="27.7" spread="10.2"/>
                    <measurement group_id="B3" value="28.0" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Development of Diabetes</title>
        <description>New-onset diabetes was based on annual glycemic testing of fasting plasma glucose, glycated hemoglobin, and 2-hour post-load plasma glucose and semiannual testing of fasting plasma glucose and glycated hemoglobin. If two or three of the glycemic measures met the 2010 ADA thresholds for diabetes, the participant was considered to have met the diabetes outcome. When only the measure for fasting plasma glucose or glycated hemoglobin met the threshold, confirmatory testing was performed for the positive measure within 8 weeks. If only the measure for 2-hour post-load plasma glucose met the threshold, then a 75-g oral glucose tolerance test to reassess all three glycemic measures was repeated. If the repeat measure was positive or both fasting plasma glucose and glycated hemoglobin were positive (in the case of a repeat oral glucose tolerance test), than the participant was considered to have met the diabetes outcome.</description>
        <time_frame>Approximately 48 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One pill daily&#xD;
Placebo: Administered as one soft-gel pill daily by mouth</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D (Cholecalciferol)</title>
            <description>One vitamin D pill daily&#xD;
Vitamin D (Cholecalciferol): Vitamin D (Cholecalciferol) 4000 IU, administered as 1 soft-gel pill daily by mouth.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Development of Diabetes</title>
          <description>New-onset diabetes was based on annual glycemic testing of fasting plasma glucose, glycated hemoglobin, and 2-hour post-load plasma glucose and semiannual testing of fasting plasma glucose and glycated hemoglobin. If two or three of the glycemic measures met the 2010 ADA thresholds for diabetes, the participant was considered to have met the diabetes outcome. When only the measure for fasting plasma glucose or glycated hemoglobin met the threshold, confirmatory testing was performed for the positive measure within 8 weeks. If only the measure for 2-hour post-load plasma glucose met the threshold, then a 75-g oral glucose tolerance test to reassess all three glycemic measures was repeated. If the repeat measure was positive or both fasting plasma glucose and glycated hemoglobin were positive (in the case of a repeat oral glucose tolerance test), than the participant was considered to have met the diabetes outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1212"/>
                <count group_id="O2" value="1211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="323"/>
                    <measurement group_id="O2" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: 25OHD Concentration</title>
        <time_frame>Approximately 48 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Race (as a Proxy for Skin Pigmentation)</title>
        <description>Race and ethnic group were reporting by the participant. The category &quot;other&quot; includes American Indian or Alaska Native; Native Hawaiian or other Pacific Islander; and other race. Ethnic group includes any race.</description>
        <time_frame>Approximately 48 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One pill daily&#xD;
Placebo: Administered as one soft-gel pill daily by mouth</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D (Cholecalciferol)</title>
            <description>One vitamin D pill daily&#xD;
Vitamin D (Cholecalciferol): Vitamin D (Cholecalciferol) 4000 IU, administered as 1 soft-gel pill daily by mouth.</description>
          </group>
        </group_list>
        <measure>
          <title>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Race (as a Proxy for Skin Pigmentation)</title>
          <description>Race and ethnic group were reporting by the participant. The category &quot;other&quot; includes American Indian or Alaska Native; Native Hawaiian or other Pacific Islander; and other race. Ethnic group includes any race.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1212"/>
                <count group_id="O2" value="1211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Race: White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="806"/>
                    <measurement group_id="O2" value="810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race: Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315"/>
                    <measurement group_id="O2" value="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race: Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethnic Group: Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethnic Group: Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1107"/>
                    <measurement group_id="O2" value="1091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Pre-diabetes Criteria (Two vs. Three Criteria)</title>
        <description>Participants met at least two of three glycemic criteria for prediabetes: fasting plasma glucose level, 100 to 125 mg per deciliter (5.6 to 6.9 mmol per liter); plasma glucose level 2 hours after a 75-g oral glucose load, 140 to 199 mg per deciliter (7.8 to 11.0 mmol per liter) (impaired glucose tolerance); and glycated hemoglobin level, 5.7 to 6.4% (39 to 47 mmol per mole).</description>
        <time_frame>Approximately 48 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One pill daily&#xD;
Placebo: Administered as one soft-gel pill daily by mouth</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D (Cholecalciferol)</title>
            <description>One vitamin D pill daily&#xD;
Vitamin D (Cholecalciferol): Vitamin D (Cholecalciferol) 4000 IU, administered as 1 soft-gel pill daily by mouth.</description>
          </group>
        </group_list>
        <measure>
          <title>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Pre-diabetes Criteria (Two vs. Three Criteria)</title>
          <description>Participants met at least two of three glycemic criteria for prediabetes: fasting plasma glucose level, 100 to 125 mg per deciliter (5.6 to 6.9 mmol per liter); plasma glucose level 2 hours after a 75-g oral glucose load, 140 to 199 mg per deciliter (7.8 to 11.0 mmol per liter) (impaired glucose tolerance); and glycated hemoglobin level, 5.7 to 6.4% (39 to 47 mmol per mole).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1212"/>
                <count group_id="O2" value="1211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Met all three criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="429"/>
                    <measurement group_id="O2" value="427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Met two criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="783"/>
                    <measurement group_id="O2" value="784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: BMI</title>
        <time_frame>Approximately 48 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One pill daily&#xD;
Placebo: Administered as one soft-gel pill daily by mouth</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D (Cholecalciferol)</title>
            <description>One vitamin D pill daily&#xD;
Vitamin D (Cholecalciferol): Vitamin D (Cholecalciferol) 4000 IU, administered as 1 soft-gel pill daily by mouth.</description>
          </group>
        </group_list>
        <measure>
          <title>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: BMI</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1212"/>
                <count group_id="O2" value="1211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="429"/>
                    <measurement group_id="O2" value="435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="783"/>
                    <measurement group_id="O2" value="776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Waist Circumference</title>
        <time_frame>Approximately 48 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One pill daily&#xD;
Placebo: Administered as one soft-gel pill daily by mouth</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D (Cholecalciferol)</title>
            <description>One vitamin D pill daily&#xD;
Vitamin D (Cholecalciferol): Vitamin D (Cholecalciferol) 4000 IU, administered as 1 soft-gel pill daily by mouth.</description>
          </group>
        </group_list>
        <measure>
          <title>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Waist Circumference</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1212"/>
                <count group_id="O2" value="1211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;Median of 104.2 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="585"/>
                    <measurement group_id="O2" value="620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥Median of 104.2 cm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="627"/>
                    <measurement group_id="O2" value="591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Age</title>
        <time_frame>Approximately 48 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One pill daily&#xD;
Placebo: Administered as one soft-gel pill daily by mouth</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D (Cholecalciferol)</title>
            <description>One vitamin D pill daily&#xD;
Vitamin D (Cholecalciferol): Vitamin D (Cholecalciferol) 4000 IU, administered as 1 soft-gel pill daily by mouth.</description>
          </group>
        </group_list>
        <measure>
          <title>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1212"/>
                <count group_id="O2" value="1211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>25-44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45-59</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="439"/>
                    <measurement group_id="O2" value="468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="670"/>
                    <measurement group_id="O2" value="637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Geographic Location (as a Proxy for Sun Exposure)</title>
        <time_frame>Approximately 48 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One pill daily&#xD;
Placebo: Administered as one soft-gel pill daily by mouth</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D (Cholecalciferol)</title>
            <description>One vitamin D pill daily&#xD;
Vitamin D (Cholecalciferol): Vitamin D (Cholecalciferol) 4000 IU, administered as 1 soft-gel pill daily by mouth.</description>
          </group>
        </group_list>
        <measure>
          <title>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Geographic Location (as a Proxy for Sun Exposure)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1212"/>
                <count group_id="O2" value="1211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At or above 37° north latitude</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="898"/>
                    <measurement group_id="O2" value="892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Below 37° north latitude</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="314"/>
                    <measurement group_id="O2" value="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Calcium Intake From Supplements</title>
        <time_frame>Approximately 48 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>One pill daily&#xD;
Placebo: Administered as one soft-gel pill daily by mouth</description>
          </group>
          <group group_id="O2">
            <title>Vitamin D (Cholecalciferol)</title>
            <description>One vitamin D pill daily&#xD;
Vitamin D (Cholecalciferol): Vitamin D (Cholecalciferol) 4000 IU, administered as 1 soft-gel pill daily by mouth.</description>
          </group>
        </group_list>
        <measure>
          <title>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Calcium Intake From Supplements</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1212"/>
                <count group_id="O2" value="1211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="793"/>
                    <measurement group_id="O2" value="826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any intake</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="419"/>
                    <measurement group_id="O2" value="385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Plasma 25OHD Concentration.</title>
        <time_frame>Approximately 48 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events.</title>
        <time_frame>Approximately 48 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Pressure as a Continuous Variable.</title>
        <time_frame>Approximately 48 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Discontinue Study Pills.</title>
        <time_frame>Approximately 48 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FPG as a Continuous Variable.</title>
        <time_frame>Every 12 months for approximately 48 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 2hPG as a Continuous Variable.</title>
        <time_frame>Every 12 months for approximately 48 months.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HbA1c as a Continuous Variable.</title>
        <time_frame>Every 6 months for approximately 48 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of Insulin Resistance (Derived From the OGTT).</title>
        <time_frame>Every 12 months for approximately 48 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of Beta Cell Secretion (Derived From the OGTT)</title>
        <time_frame>Every 12 months for approximately 48 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Identification of Characteristics Associated With the Variability in Achieved 25OHD Concentration.</title>
        <time_frame>Every 12 months for approximately 48 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Sex</title>
        <time_frame>Approximately 48 months.</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: Ethnicity</title>
        <time_frame>Approximately 48 months.</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Variability of Response to Vitamin D Supplementation by Baseline Characteristic: 2 Hour Plasma Glucose</title>
        <time_frame>Approximately 48 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to Development of Cancer.</title>
        <time_frame>Approximately 48 months.</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time to Development of Cardiovascular Event.</title>
        <time_frame>Approximately 48 months.</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence of Cancer in a Pre-diabetes Population Defined by the Modern American Diabetes Association Criteria.</title>
        <time_frame>Approximately 48 months.</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence of Cardiovascular Disease in a Pre-diabetes Population Defined by the Modern American Diabetes Association Criteria.</title>
        <time_frame>Approximately 48 months.</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Quality of Life and Mood Scores in Pre-diabetes Population Using a Validated Instrument (PROMIS-29 Profile v2.0 and a General Question on Perception of Overall Health From the PROMIS Scale 1.2).</title>
        <time_frame>One time assessment at the month 24 visit.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2.5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>One pill daily&#xD;
Placebo: Administered as one soft-gel pill daily by mouth</description>
        </group>
        <group group_id="E2">
          <title>Vitamin D (Cholecalciferol)</title>
          <description>One vitamin D pill daily&#xD;
Vitamin D (Cholecalciferol): Vitamin D (Cholecalciferol) 4000 IU, administered as 1 soft-gel pill daily by mouth.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1211"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="153" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="173" subjects_at_risk="1211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1211"/>
              </event>
              <event>
                <sub_title>Hospitalization</sub_title>
                <counts group_id="E1" subjects_affected="148" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="1211"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1212"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="1211"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1212"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="1211"/>
              </event>
              <event>
                <sub_title>Fasting urine calcium: creatinine ratio &gt;0.375</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1211"/>
              </event>
              <event>
                <sub_title>Low estimated glomerular filtration rate</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1212"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="1211"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="1212"/>
                <counts group_id="E2" events="25" subjects_affected="24" subjects_at_risk="1211"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Anastassios Pittas</name_or_title>
      <organization>Division of Endocrinology, Diabetes, and Metabolism, Tufts Medical Center</organization>
      <phone>617-636-3232</phone>
      <email>apittas@tuftsmedicalcenter.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

